Search Result

Results for "

Farnesyl diphosphate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Farnesyl Transferase (4) Bacterial (4) Endogenous Metabolite (3) HCV (2) Isotope-Labeled Compounds (3) Parasite (1) TRP Channel (3)
By Research Areas:	Cancer (10) Infection (6) Metabolic Disease (5) Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Farnesyl Transferase UGT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	TRP Channel Endogenous Metabolite	Neurological Disease
Farnesyl pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-11101

Alendronate sodium hydrate 5 Publications Verification Alendronate; MK 217; G-704650 Adronat	Others	Cancer
Alendronate (sodium hydrate) is a farnesyl diphosphate synthase inhibitor with IC₅₀ of 460 nM.

HY-118946

BPH-1358 NSC50460	Bacterial	Infection Cancer
BPH-1358 (NSC50460) is a potent human farnesyl diphosphate synthase (FPPS) and *undecaprenyl diphosphate* synthase (UPPS) inhibitor with IC₅₀s of 1.8 μM and 110 nM, respectively, and is active against S. aureus** in vitro (MIC ~250 ng/mL) .

HY-B0631

Alendronic acid 5 Publications Verification	Others	Cancer
Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .

HY-113037S1

Farnesyl pyrophosphate-d3 Farnesyl diphosphate-d₃	TRP Channel Endogenous Metabolite Isotope-Labeled Compounds	Neurological Disease
Farnesyl pyrophosphate-d₃ (Farnesyl diphosphate-d₃) is deuterium-labeled Farnesyl pyrophosphate (HY-113037) .

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	TRP Channel Endogenous Metabolite	Neurological Disease
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-126825

NE21650	Others	Metabolic Disease
NE21650 potently inhibits farnesyl diphosphate (FPP) synthase. NE21650 is a weak inhibitor of *isopentenyl diphosphate* (IPP)** isomerase. NE21650 is a potent inhibitor of protein prenylation in osteoclasts and macrophages and bone resorption in vitro .

HY-11101S

Alendronate-d6 sodium hydrate	Isotope-Labeled Compounds	Cancer
Alendronate-d₆ sodium hydrate is deuterated labeled Alendronate sodium hydrate (HY-11101). Alendronate sodium hydrate is a farnesyl diphosphate synthase inhibitor with IC₅₀ of 460 nM.

HY-11101R

Alendronate (sodium hydrate) (Standard)	Others	Cancer
Alendronate (sodium hydrate) (Standard) is the analytical standard of Alendronate (sodium hydrate). This product is intended for research and analytical applications. Alendronate (sodium hydrate) is a farnesyl diphosphate synthase inhibitor with IC₅₀ of 460 nM.

HY-118946B

BPH-1358 mesylate NSC50460 mesylate	Bacterial	Infection Cancer
BPH-1358 mesylate (NSC50460 mesylate) is a potent human farnesyl diphosphate synthase (FPPS) and *undecaprenyl diphosphate* synthase (UPPS) inhibitor with IC₅₀s of 1.8 μM and 110 nM, respectively. BPH-1358 mesylate is active against S. aureus** in vitro (MIC ~250 ng/mL) .

HY-118946A

BPH-1358 free base NSC50460 free base	Bacterial	Infection Cancer
BPH-1358 free base (NSC50460 free base) is a potent human farnesyl diphosphate synthase (FPPS) and *undecaprenyl diphosphate* synthase (UPPS) inhibitor with IC₅₀s of 1.8 μM and 110 nM, respectively, and is active against S. aureus** in vitro (MIC ~250 ng/mL) .

HY-161336

Alendronate prodrug-1	Others	Cancer
Alendronate prodrug-1(compound 2) is an inhibitor of farnesyl diphosphate synthase (FPPS). Alendronate prodrug-1 has an antiproliferative effect with an IC₅₀ value of 34.0 μM .

HY-113752

MMV019313	Parasite	Infection
MMV019313 is a potent, non-bisphosphonate inhibitor of farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS) with an IC₅₀ of 0.82 µM. MMV019313 has activity against P. falciparum (Parasite) .

HY-B0631S

Alendronic acid-d6	Isotope-Labeled Compounds	Cancer
Alendronic acid-d₆ is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].

HY-116254

L-739750	Farnesyl Transferase	Others
L-739750 is a selective protein farnesyltransferase (PFTase) inhibitor (IC₅₀: 0.4 nM). PFTase utilizes farnesyl diphosphate to farnesylate the cysteine residue of protein substrates having a C-terminal CAAX motif. L-739750 is a selective CAAX peptidomimetic .

HY-16274

Lapaquistat acetate TAK-475	Farnesyl Transferase	Metabolic Disease
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .

HY-100313A

YM-53601 2 Publications Verification	Farnesyl Transferase HCV	Infection Metabolic Disease
YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-149149

Incadronic acid	Bacterial	Infection Metabolic Disease Cancer
Incadronic acid inhibits growth of Dictyostelium discoideum with an IC₅₀ of 1.6 μM. Incadronic acid binds the farnesyl diphosphate synthase (FPPS) in Leishmania major with the K_i of 23 nM. Incadronic acid inhibits the bone resorption and reduces bone loss, that can be used in osteoporosis research. Incadronic acid inhibits the proliferation of cells RAW264.7, PC-3 and MCF-7 with IC₅₀ of 48 to 228.6 µM .

HY-100313

YM-53601 free base	Farnesyl Transferase HCV	Metabolic Disease
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	TRP Channel Endogenous Metabolite
Farnesyl pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	TRP Channel Endogenous Metabolite
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-100313

YM-53601 free base	Structural Classification Alkaloids Carbazole Alkaloids	Farnesyl Transferase HCV
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

Species:	Human (3)
Tag:	His (3)
Source:	HEK293 (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P72193

	FDFT1 Protein, Human (His) DGPT; ERG9; Farnesyl diphosphate Farnesyltransferase; Farnesyl-diphosphate Farnesyltransferase; FDFT_HUMAN; FDFT1; FPP:FPP Farnesyltransferase; SQS; Squalene synthase; Squalene synthetase; SS	Human	E. coli
	FDFT1 is a key enzyme in cellular metabolism responsible for coordinating the condensation of two farnesyl pyrophosphate (FPP) molecules, a key step in sterol biosynthesis. The process proceeds in two distinct steps: First, two FPP molecules react to form the stable squalene diphosphate intermediate (PSQPP), releasing protons and inorganic diphosphate. FDFT1 Protein, Human (His) is the recombinant human-derived FDFT1 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P70224

	GGPS1 Protein, Human (His) rHuGeranylgeranyl pyrophosphate synthase/GGPS1, His; Geranylgeranyl Pyrophosphate Synthase; GGPP Synthase; GGPPSase; (2E; 6E)-Farnesyl diphosphate Synthase; Dimethylallyltranstransferase; Farnesyl diphosphate Synthase; Farnesyltranstransferase; Geranylgeranyl diphosphate Synthase; Geranyltranstransferase; GGPS1	Human	E. coli
	The GGPS1 protein is responsible for catalyzing the trans-addition of three molecules of isopentenyl pyrophosphate (IPP) to dimethylallyl pyrophosphate (DMAPP) to synthesize geranylgeranyl pyrophosphate. This compound is an important precursor for the biosynthesis of carotenoids and geranylated proteins. GGPS1 Protein, Human (His) is the recombinant human-derived GGPS1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of GGPS1 Protein, Human (His) is 300 a.a., with molecular weight of ~35.0 kDa.

HY-P702577

	GGPS1 Protein, Human (HEK293, His) rHuGeranylgeranyl pyrophosphate synthase/GGPS1, His; Geranylgeranyl Pyrophosphate Synthase; GGPP Synthase; GGPPSase; (2E; 6E)-Farnesyl diphosphate Synthase; Dimethylallyltranstransferase; Farnesyl diphosphate Synthase; Farnesyltranstransferase; Geranylgeranyl diphosphate Synthase; Geranyltranstransferase; GGPS1	Human	HEK293

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0631S

Alendronic acid-d6
Alendronic acid-d₆ is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].

HY-113037S1

Farnesyl pyrophosphate-d3
Farnesyl pyrophosphate-d₃ (Farnesyl diphosphate-d₃) is deuterium-labeled Farnesyl pyrophosphate (HY-113037) .

HY-11101S

Alendronate-d6 sodium hydrate
Alendronate-d₆ sodium hydrate is deuterated labeled Alendronate sodium hydrate (HY-11101). Alendronate sodium hydrate is a farnesyl diphosphate synthase inhibitor with IC₅₀ of 460 nM.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Farnesyl diphosphate

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products